FindTrial
Sign In

Associations of gene polymorphisms with type 2 diabetes mellitus and anti-diabetic drug therapeutic efficacy

Associations of gene polymorphisms with type 2 diabetes mellitus and anti-diabetic drug therapeutic efficacy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-CCC-13003536
Enrollment
Unknown
Registered
2013-04-06
Start date
2010-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

control group:no
Type 2 Diabetes group:treated with Nateglinide or Repaglinide to control blood glucose

Sponsors

The affiliated hospital of Xuzhou Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 70 Years

Inclusion criteria

Inclusion criteria: The?diagnosis?of?T2DM?was based on the 1999 criteria of the World Health Organization, namely, fasting plasma glucose(FPG)level>=7.0 mmol/L and/or postprandial glucose(PPG)level>=11.1 mmol/L.

Exclusion criteria

Exclusion criteria: Patients with type 1 diabetes, secondary diabetes, gestational diabetes and severe liver and kidney disease were excluded.

Design outcomes

Primary

MeasureTime frame
KCNQ1, NOS1AP, TCF7L2, PPAR-d and MTNR1B gene;—

Countries

China

Contacts

Public ContactXiaoxing Yin, Wei Li, Qian Lu, Yan Wang

Xuzhou Medical College

yinxx@xzmc.edu.cn+86 0516 83262009

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 22, 2026